PTC Therapeutics Establishes Office At Dubai Science Park To Enhance Rare Disease Treatment Access

PTC Therapeutics, a global leader in biopharmaceuticals for rare diseases, has inaugurated its Middle East and North Africa (MENA) office at Dubai Science Park. This move aims to improve access to transformative medicines for patients with rare diseases in the region. The new facility will act as a regional hub, focusing on delivering PTC's innovative treatments and solutions to enhance health outcomes.

Approximately 350 million people worldwide are affected by rare diseases, with around 2.8 million residing in the Middle East. PTC Therapeutics specialises in developing therapies for these conditions globally. The company's presence in the MENA region underscores its commitment to serving more patients across various therapeutic areas.

Zeina Sfeir, Head of MENA at PTC Therapeutics, expressed enthusiasm about establishing a physical presence in the region. "We are excited to have a physical presence in the region and are looking forward to serve many more patients, across diverse portfolio of therapeutics areas, and with unwavering commitment," she stated. This expansion aligns with PTC's mission to provide innovative treatments for rare disease patients.

Dubai Science Park serves as a collaborative platform for researchers, clinicians, and biological pharmacists. Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group PJSC, highlighted the importance of partnerships like that with PTC Therapeutics. "Dubai Science Park’s ecosystem is a uniting platform for innovative researchers, clinicians, and biological pharmacists," he said.

For nearly a decade, PTC has built strong partnerships with regional stakeholders. These collaborations have significantly improved outcomes for rare disease patients through transformative treatments such as those for Duchenne Muscular Dystrophy (DMD) and gene therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

The establishment of PTC's office in Dubai supports local initiatives like the Dubai Research and Development Programme and Dubai Economic Agenda ‘D33’. It also contributes to the broader vision outlined in 'We the UAE 2031'. The collaboration between PTC Therapeutics and Dubai Science Park is expected to translate scientific advancements into effective therapies that enhance health outcomes.

The new MENA office signifies PTC's dedication to expanding its reach and impact within the region. By focusing on delivering cutting-edge treatments and fostering collaborations with local stakeholders, PTC aims to make significant strides in improving health outcomes for individuals affected by rare diseases.

With inputs from WAM